Today's Medical & Research News
Enzyme Research
Researchers from Hertie Institute for Clinical Brain Research, Department of Neurodegeneration discuss findings in enzyme research
November 6th, 2009
Fresh data on enzyme research are presented in the report 'Homo- and heterodimerization of ROCO kinases: LRRK2 kinase inhibition by the LRRK2 ROCO fragment.' "Mutations in the gene encoding leucine-rich repeat kinase 2 (LRRK2) are the most common cause of autosomal-dominant familial and late-onset sporadic Parkinson's disease (PD). LRRK2 is a large multi-domain protein featuring a GTP-binding C-terminal of Ras of complex proteins (ROC) (ROCO) domain combination unique for the ROCO protein family, directly followed by a kinase domain," investigators in Germany report. "Dimerization is a well-established phenomenon among protein kinases. Here, we confirm LRRK2 self-interaction, and provide evidence for general homo-and heterodimerization potential among the ROCO kinase family (LRRK2, LRRK1, and death-associated protein kinase 1). The ROCO domain was critically, though not exclusively involved in dimerization, as a LRRK2 deletion mutant lacking the ROCO domain retained dimeric properties. GTP binding did not appear to influence ROCO(LRRK2) self-interaction. Interestingly, ROCO(LRRK2) fragments exerted an inhibitory effect on both wild-type and the elevated G2019S LRRK2 autophosphorylation activity. Insertion of PD mutations into ROCO(LRRK2) reduced self-interaction and led to a reduction of LRRK2 kinase inhibition. Collectively, these results suggest a functional link between ROCO interactions and kinase activity of wild-type and mutant LRRK2," wrote C.L. Klein and colleagues, Hertie Institute for Clinical Brain Research, Department of Neurodegeneration. The researchers concluded: "Importantly, our finding of ROCO(LRRK2) fragment-mediated LRRK2 kinase inhibition offers a novel lead for drug design and thus might have important implications for new therapeutic avenues in PD." Klein and colleagues published their study in the Journal of Neurochemistry (Homo- and heterodimerization of ROCO kinases: LRRK2 kinase inhibition by the LRRK2 ROCO fragment. Journal of Neurochemistry, 2009;111(3):703-15). For additional information, contact C.L. Klein, Hertie Institute for Clinical Brain Research, Dept. of Neurodegeneration, University Clinics Tubingen, Germany. The publisher of the Journal of Neurochemistry can be contacted at: Blackwell Publishing Inc., 350 Main St., Malden, MA 02148, USA. Keywords: Germany, Brain Research, Enzyme Research, Genetics, Kinase, Mental Health, Neurochemistry, Neurodegenerative. This article was prepared by NewsRx editors from staff and other reports. Copyright 2009, NewsRx.com.
|
